ClinicalTrials.gg
Not yet recruitingNCT07731204LOMBALZIC'Updated Jul 28, 2026

Impact of the Receptive Music Intervention Tool (MUSIC CARE©) on Changes in the Functional Abilities of Patients With Chronic Low Back Pain

An interventional study of Receptive Music Therapy in Low Back Pain, Kinesiophobia (Fear of Movement) and Chronic Low-back Pain (cLBP), sponsored by LNA SANTE. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by LNA SANTE · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Brief Summary The goal of this clinical trial is to learn if MUSIC CARE©, a music-based therapy tool, can improve the physical abilities of people with chronic low back pain (back pain that lasts more than 3 months).

The main questions it aims to answer are:

Does MUSIC CARE© help participants better perform their daily activities? Does MUSIC CARE© lower the fear of movement in participants? Does MUSIC CARE© help participants return to work?

Why this study? Chronic low back pain is a leading cause of disability and absence from work. Physical rehabilitation is the recommended treatment. However, many participants develop a fear of movement. This fear slows down their recovery and limits the benefits of rehabilitation.

MUSIC CARE© is a digital music tool. It uses specially designed music to help participants relax and feel less pain. Researchers believe that using MUSIC CARE© before rehabilitation sessions may help participants move more freely and recover better.

How does the study work?

Researchers will compare two groups of participants:

Group 1: follows a standard rehabilitation program with MUSIC CARE© Group 2: follows a standard rehabilitation program without MUSIC CARE© This comparison will show whether MUSIC CARE© brings added benefits.

Participants will:

Take part in a rehabilitation program for 5 to 6 weeks Use MUSIC CARE© before each therapy session (Group 1 only). Complete questionnaires about their pain, fear of movement, and ability to perform daily activities.

Be followed for 6 months after the program ends, including an assessment of their return to work.

What could this study change? If results are positive, this study could confirm that MUSIC CARE© is a useful non-drug tool to support rehabilitation for people with chronic low back pain. It could help bring this approach into standard care programs, with no additional medication.

Read the detailed description

Detailed Description

Background and Rationale Chronic low back pain (CLBP) is defined as habitual lumbar pain persisting for more than three months, with possible radiation to the buttock, iliac crest, or thigh. The Haute Autorité de Santé (HAS) further distinguishes degenerative, non-degenerative, and anatomically non-related forms of the condition.

Although only approximately 10% of acute low back pain episodes progress to CLBP, this minority accounts for 70 to 90% of all direct and indirect costs associated with low back pain. CLBP is the leading cause of disability before age 45, the primary driver of sick leave, and the most frequent occupational disease in France.

Beyond pain, CLBP is characterized by a physical deconditioning syndrome, arising after weeks of restricted activity. Muscle strength and endurance decline, directly impairing functional capacity. This is often compounded by kinesiophobia (Tampa Scale of Kinesiophobia, TSK), an excessive fear of movement stemming from perceived vulnerability to painful injury, which perpetuates activity avoidance and sustains functional limitations.

Current HAS guidelines position structured active rehabilitation as the primary treatment for CLBP: it reduces pain, functional disability, and work incapacity both in the short and long term. The standard rehabilitation program at the study site is multidisciplinary, involving physiotherapy, occupational therapy (OT), adapted physical activity (APA), and psychomotricity.

Despite the recognized efficacy of these programs, clinicians observe that a subset of patients remains significantly impaired by kinesiophobia and motor inhibitions, limiting engagement in rehabilitation. Complementary approaches such as conscious breathing, guided visualization, and directed movement are routinely integrated to address these barriers.

Music therapy has emerged as a promising adjunctive non-pharmacological intervention in chronic pain management. Its analgesic and anxiolytic effects are supported by a systematic review of 25 randomized controlled trials (RCTs) reporting significant improvements in pain, anxiety, sleep quality, and quality of life in chronic pain populations. Proposed neurophysiological mechanisms include increased vagal tone, endorphin secretion, and activation of cerebral reward and emotional regulation networks, resulting in modulation of sensory, cognitive, affective, and behavioral pain components, including reduction of muscular hypertonia.

In the specific context of CLBP rehabilitation, music therapy combined with conventional rehabilitation has been shown to significantly reduce anxiety and depression, with an immediate dose-response effect on pain observed after each session. Furthermore, music may act as a motor disinhibitor by fostering self-confidence and raising awareness of the patient's own motor capacities.

MUSIC CARE© (Class 1 medical device) is the first French digital music innovation designed since 2005 for clinical pain and anxiety reduction. It uses standardized musical composition algorithms based on hypnoanalgesia principles. Its efficacy has been demonstrated across multiple pain populations, including CLBP, neurological and inflammatory pain, postoperative pain, and oncology-related pain, with significant reductions in pain intensity and analgesic and anxiolytic drug consumption.

Despite this evidence, the impact of music therapy on functional capacity and kinesiophobia in CLBP remains insufficiently studied, particularly over extended follow-up periods. Most existing studies focus on brief interventions (5 to 21 days). This study addresses this gap through an extended rehabilitation period (5 to 6 weeks) and a 6-month follow-up, enabling evaluation of medium- and long-term effects.

Study Design LOMBALZIC' is a pilot, monocentric, prospective, randomized study conducted at the Clinique Saint-Roch (Roncq, France), a day hospital (HDJ) specializing in CLBP rehabilitation. It is classified as a Research Involving the Human Person (RIPH) category 2, with minimal risks and constraints under French law (Art. L1121-1 of the Public Health Code).

Study sponsor: LNA Santé Principal investigator: Mathieu LEDUCQ, Occupational Therapist, Clinique Saint-Roch Co-investigators: Alexandre BLAIRON (Physiotherapist); Dr. Fabien MORETTO (Physical Medicine and Rehabilitation, MPR physician) Total study duration: 15 months (planned start: September 2026; planned end: November 2027) Inclusion period: 9 months Follow-up per participant: 6 months Target sample size: 34 participants (individual-level randomization) Data collection: Electronic Case Report Form (eCRF) Randomization: Centralized, performed by the LNA Santé Research Support Unit using R software, with block randomization to ensure balanced group sizes over time. Randomization arms are coded A and B for blinded statistical analysis.

The MUSIC CARE© Intervention MUSIC CARE© is a Class 1 clinically validated medical device (CE-marked), developed in France for non-pharmacological management of pain and anxiety. The device delivers personalized, standardized receptive music therapy based on hypnoanalgesia principles.

Each musical sequence follows a standardized "U-sequence" protocol comprising three phases:

Induction phase: an initially stimulating rhythm aligned with the participant's emotional state, characterized by a progressive decrease in tempo, orchestral complexity, sound frequency, and volume.

Relaxation phase: a reduced number of instruments and a slow tempo enabling deep relaxation.

Awakening phase: a progressive return toward initial musical parameters, without reaching the same stimulation level as at the outset.

The MUSIC CARE© catalogue includes 58 musical sequences, almost exclusively instrumental and always without lyrics, spanning a wide range of musical styles, harmonies, timbres, and melodies to accommodate individual sensitivities, cultural backgrounds, and listening preferences. All sequences are original compositions by professional musicians, designed to meet the U-sequence specifications and to avoid potential emotional revivals triggered by familiar pieces.

Session durations can range from 15 to 90 minutes. In this study, each session is set at 20 minutes.

In the interventional group, each participant receives a 20-minute MUSIC CARE© session each day of their HDJ stay, prior to their standard rehabilitation sessions. The participant is seated alone and comfortably in a dedicated room, wearing headphones connected to the MUSIC CARE© tablet. The U-sequence is pre-selected and configured by the investigator according to the participant's musical preferences collected at inclusion. Immediately following the session, the participant proceeds to their standard rehabilitation program.

The control group receives the standard multidisciplinary rehabilitation program only, without MUSIC CARE©.

MUSIC CARE© is already in use across LNA Santé medico-social facilities. A training session will be conducted before the study begins to ensure standardized use across all personnel involved.

Standard Rehabilitation Program (Both Groups)

All participants follow a structured multidisciplinary rehabilitation program lasting 5 to 6 weeks, organized in four progressive phases:

Week 1: Assessment and orientation Weeks 2 to 3: Mobility work and motor control Weeks 3 to 4: Trunk strengthening and stabilization Weeks 5 to 6: Preparation for professional reintegration, including vocational situational training and self-maintenance exercise program

Each discipline integrates specific work on pain-related beliefs, fears, and motor inhibitions throughout the program. The detailed intervention schedule by discipline and week is provided in Annex X of the protocol.

Study Procedures and Visit Schedule

Pre-inclusion visit (VS): The MPR physician identifies eligible participants during the pre-admission consultation and provides oral information about the study. A participant information letter and a MUSIC CARE© presentation document are provided.

Inclusion visit (Day 0 / J0): On the first day of HDJ admission, written informed consent is obtained. Musical preferences are collected to personalize the intervention.

Baseline and Randomization visit (Day 1 / J1 ±1 day): Baseline assessments are performed (EIFEL questionnaire, TAMPA questionnaire, PILE TEST). Clinical data are collected from the admission file. Randomization is performed, and participants are allocated to their respective group.

Follow-up during stay (J0 to S5/S6): Adverse events (AEs) potentially related to MUSIC CARE© tolerance are monitored throughout the stay.

End-of-stay visit (Weeks 5 to 6 / S5-S6): EIFEL and TAMPA questionnaires are completed; the PILE TEST is performed; a professional situation questionnaire is administered. Two pre-stamped envelopes containing the 3-month and 6-month questionnaires are provided to the participant.

3-month follow-up (J90 ±7 days): EIFEL, TAMPA, and professional situation questionnaires are returned by post. The investigator contacts participants beforehand as a reminder. In case of non-response within 2 weeks, a phone reminder and a second postal mailing are attempted.

6-month follow-up (J180 ±7 days): Same procedure as the 3-month visit. After this visit, participant involvement in the study is complete.

Study withdrawal criteria: Participants may be withdrawn in the event of full hospitalization (24h or more), clinical deterioration preventing protocol continuation, non-compliance (less than 80% adherence to the rehabilitation program), participant withdrawal, or investigator decision.

Assessment Tools EIFEL (Échelle d'Incapacité Fonctionnelle pour l'Évaluation des Lombalgies): A validated 24-item self-administered questionnaire specifically developed to assess the impact of low back pain on activities of daily living. It is the primary outcome instrument.

TAMPA Scale of Kinesiophobia (TSK): A validated 17-item self-administered questionnaire assessing kinesiophobia, scored on a 4-point Likert scale.

PILE TEST (Progressive Isoinertial Lifting Evaluation): A functional capacity test assessing physical capacity and functional endurance through a progressive lifting task (approximately 2 to 3 minutes).

Professional situation questionnaire: A study-specific questionnaire assessing employment status and return-to-work conditions.

Given the nature of the intervention, blinding of participants and caregivers is not feasible. To limit expectation bias and contextual effects, questionnaires are completed autonomously by participants, and assessments are conducted using identical standardized procedures in both groups.

Statistical Analysis Plan

The target sample of 34 participants was determined based on the recruitment capacity of the site over the inclusion period. Given the exploratory nature of the study, this sample size was estimated to detect a mean EIFEL score difference of approximately 1.75 points between groups, with 99% statistical power.

Analyses will be conducted both in Intention to Treat (ITT) (all included, randomized, and measured participants at S5/S6) and Per Protocol (PP) (excluding participants with major protocol deviations).

Statistical methods:

Quantitative variables: described by mean, standard deviation, median, quartiles, and extremes. Normality assessed by Shapiro-Wilk test. Group comparisons by Student t-test or Mann-Whitney test according to distribution.

Qualitative variables: described by frequencies and percentages. Compared by Pearson Chi² with continuity correction (or Monte-Carlo simulation with 20,000 runs if any cell is below 5), and by Fisher's test for primary and secondary objectives.

EIFEL and TAMPA total scores and PILE TEST results: compared between groups at each visit using the appropriate test (t-test or Mann-Whitney). Paired tests will assess intra-group evolution between visits. Longitudinal mixed linear regressions will model the time effect, with baseline score as covariate.

Professional situation: analyzed as a categorical variable with Fisher's test.

Missing data at M3 and M6: imputed using the Last Observation Carried

Forward (LOCF) method. Sensitivity analyses adjusted for potential confounders will be performed.

Adverse events: counted per individual and compared by type between study arms.

All tests are bilateral with a global alpha risk of 5%. A p-value below 0.05 will be considered statistically significant. All confidence intervals are presented at the 95% level. Statistical analyses will be performed using R software (v4.3.2 or later) by the LNA Santé Research Support Unit.

Benefit-Risk Assessment

Expected benefits for participants:

Significant improvement in functional capacity in activities of daily living Reduction in kinesiophobia Increased functional endurance

Identified risks (minimal and infrequent):

Transient anxiety increase (paradoxical reaction) Emotional reactivation triggered by music associated with past uncomfortable or distressing experiences

In either case, the MUSIC CARE© session is immediately interrupted, the participant is reassured by the investigator, and medical advice is sought if needed. Depending on severity, the intervention may be permanently discontinued for that participant, without affecting standard rehabilitation care or care quality.

Regulatory and Ethical Framework

This study is classified as RIPH category 2 (minimal risks and constraints) under Art. L1121-1 of the French Public Health Code (Code de la santé publique). It does not require ANSM authorization. Authorization from a Comité de Protection des Personnes (CPP) is required and has been requested. Data management complies with MR-001 reference methodology under the French Data Protection Act and GDPR. Data are pseudonymized and archived for 15 years following study closure. The study is funded exclusively by LNA Santé. The investigative team and sponsor declare no conflicts of interest with the manufacturer of MUSIC CARE©.

02

Conditions studied

  • Low Back Pain
  • Kinesiophobia (Fear of Movement)
  • Chronic Low-back Pain (cLBP)

Keywords

  • Low Back Pain
  • Chronic Pain
  • Music Therapy
  • Physical Functional Performance
  • Kinesiophobia
  • Fear of Movement
  • Rehabilitation
  • Exercise Therapy
  • Return to Work
  • Non-Pharmacological Intervention
  • Patient Reported Outcome Measures
  • Functional Capacity
03

In context

Low Back Pain

2,922 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

This study's planned enrollment of 34 is below the median of 60 across 2,364 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

LNA SANTE is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic low back pain by a Physical Medicine and Rehabilitation (PMR) physician, defined as lumbar pain and/or pain radiating to the lower limb that affects daily and professional activities and has lasted more than 3 months
  • If surgery was performed, it must have been done at least 3 months before entering the study
  • Adult (18 years of age or older) admitted to the day hospital at Clinique Saint-Roch for a chronic low back pain rehabilitation program
  • Considered able to return to work, as assessed by the PMR physician during the pre-admission consultation, with no medical to resuming professional activity
  • Affiliated with a French social security scheme
  • Has given written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Hearing impairment that would prevent the use of the MUSIC CARE© device
  • Medical to hydrotherapy (balneotherapy)
  • Symptomatic disc herniation
  • Vertebral fracture or history of recent vertebral fracture within the past 2 years
  • Unstable spondylolisthesis
  • Disc-vertebral infection (spondylodiscitis)
  • Inflammatory rheumatic disease such as ankylosing spondylitis (spondyloarthritis) or rheumatoid arthritis
  • Constitutional connective tissue disorder such as Ehlers-Danlos syndrome or Marfan syndrome
  • Severe, unstabilized, or decompensated psychiatric disorder, including psychotic disorders, acute-phase bipolar disorder, or severe major depressive episode
  • Central nervous system neurological disease such as multiple sclerosis, stroke, or Parkinson's disease
  • Peripheral neuropathy of the lower limbs
  • Unstabilized cardiovascular disease
  • Active cancer treatment or cancer diagnosis within the past 2 years
  • Surgery for a reason other than low back pain within the past 6 months
  • Currently retired (not in active employment)
  • Currently enrolled in another interventional research study
  • Persons under legal protection as defined by Articles L.1121-5 to L.1121-8 of the French Public Health Code, including:
  • Persons under guardianship, curatorship, or judicial protection
  • Minors (under 18 years of age)
  • Pregnant or breastfeeding women
  • Any person subject to a legal protection measure or unable to freely provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Interventional Group : MUSIC CARE© Combined with Standard Rehabilitation

    Participants receive a daily 20-minute receptive music session using the MUSIC CARE© device before each rehabilitation session throughout the 5-to-6-week day hospital stay. Seated comfortably in a dedicated room with headphones, participants listen to a personalized "U-sequence" (induction, deep relaxation, awakening phases). They then proceed to the standard multidisciplinary rehabilitation program, including physiotherapy, occupational therapy, adapted physical activity, and psychomotricity.

    Device: Receptive Music Therapy

  • No intervention
    Control Group : Standard Rehabilitation Alone

    Participants receive the standard multidisciplinary rehabilitation program for chronic low back pain over 5 to 6 weeks, including physiotherapy, occupational therapy, adapted physical activity, and psychomotricity. The program progresses from assessment and motor control work to trunk strengthening and preparation for professional reintegration. No music-based intervention is added.

Interventions

  • DeviceReceptive Music Therapy

    MUSIC CARE© is a Class 1 validated medical device delivering personalized receptive music therapy based on hypnoanalgesia principles. Each session follows a standardized "U-sequence" protocol comprising three phases: an induction phase with gradually decreasing tempo and orchestral complexity; a deep relaxation phase with slow tempo and minimal instrumentation; and a progressive awakening phase. Sessions are set at 20 minutes, administered daily before standard rehabilitation sessions throughout the 5-to-6-week day hospital stay. The sequence is pre-personalized by the investigator according to participant musical preferences collected at inclusion. The participant is seated alone in a dedicated room, wearing headphones connected to the MUSIC CARE© tablet.

    Also known as: Receptive Music Intervention; Digital Music Therapy Tool

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Functional Disability as Assessed by the EIFEL Questionnaire at End of Stay

    The EIFEL (Échelle d'Incapacité Fonctionnelle pour l'Évaluation des Lombalgies) is a validated 24-item self-administered questionnaire, adapted from the Roland-Morris Disability Questionnaire. Each item is answered yes (1) or no (0). The total score ranges from 0 to 24, where 0 indicates no functional disability and 24 indicates maximum functional disability. A higher score reflects greater impairment in daily life activities. A decrease in score indicates improvement in functional capacity. The minimal clinically important difference (MCID) is generally considered to be 2 to 3 points.

    Time frame: Baseline (Day 1) and end of stay (Weeks 5 to 6)

Secondary outcomes

  1. Change from Baseline in Functional Disability as Assessed by the EIFEL Questionnaire at 3 Months

    The EIFEL is a validated 24-item self-administered questionnaire. Total score ranges from 0 (no disability) to 24 (maximum disability). A decrease in score reflects improvement in functional capacity in daily life activities. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 3 months post-discharge (Day 90 ± 7 days)

  2. Change from Baseline in Functional Disability as Assessed by the EIFEL Questionnaire at 6 Months

    The EIFEL is a validated 24-item self-administered questionnaire. Total score ranges from 0 (no disability) to 24 (maximum disability). A decrease in score reflects improvement in functional capacity in daily life activities. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 6 months post-discharge (Day 180 ± 7 days)

  3. Change from Baseline in Physical Capacity and Functional Endurance as Assessed by the PILE Test at End of Stay

    The PILE Test (Progressive Isoinertial Lifting Evaluation) is an objective functional capacity test assessing physical endurance through a progressive incremental lifting task performed over 2 to 3 minutes. The participant lifts increasing loads from floor to waist height until a stopping criterion is reached (pain, exhaustion, or predefined safety threshold). Results are expressed in kilograms lifted and/or as a percentage of body weight. A higher score reflects greater physical capacity and functional endurance.

    Time frame: Baseline (Day 1) and end of stay (Weeks 5 to 6)

  4. Change from Baseline in Kinesiophobia as Assessed by the Tampa Scale of Kinesiophobia at End of Stay

    The Tampa Scale of Kinesiophobia (TSK) is a validated 17-item self-administered questionnaire assessing fear of movement and re-injury. Each item is scored on a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). Total score ranges from 17 to 68, where higher scores indicate greater kinesiophobia. A score of 37 or above is commonly used as a threshold for clinically significant kinesiophobia. A decrease in score indicates reduced fear of movement.

    Time frame: Baseline (Day 1) and end of stay (Weeks 5 to 6)

  5. Change from Baseline in Kinesiophobia as Assessed by the Tampa Scale of Kinesiophobia at 3 Months

    The Tampa Scale of Kinesiophobia (TSK) is a validated 17-item self-administered questionnaire. Total score ranges from 17 (no kinesiophobia) to 68 (maximum kinesiophobia). A decrease in score reflects reduced fear of movement. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 3 months post-discharge (Day 90 ± 7 days)

  6. Change from Baseline in Kinesiophobia as Assessed by the Tampa Scale of Kinesiophobia at 6 Months

    The Tampa Scale of Kinesiophobia (TSK) is a validated 17-item self-administered questionnaire. Total score ranges from 17 (no kinesiophobia) to 68 (maximum kinesiophobia). A decrease in score reflects reduced fear of movement. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 6 months post-discharge (Day 180 ± 7 days)

  7. Change from Baseline in Professional Situation at End of Stay

    Professional situation is assessed using a study-specific self-administered questionnaire evaluating employment status (working, on sick leave, unemployed, other) and return-to-work conditions. The questionnaire captures changes in occupational status and the conditions under which professional activity has been resumed or is anticipated.

    Time frame: Baseline (Day 1) and end of stay (Weeks 5 to 6)

  8. Change from Baseline in Professional Situation at 3 Months

    Professional situation is assessed using a study-specific self-administered questionnaire evaluating employment status and return-to-work conditions. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 3 months post-discharge (Day 90 ± 7 days)

  9. Change from Baseline in Professional Situation at 6 Months

    Professional situation is assessed using a study-specific self-administered questionnaire evaluating employment status and return-to-work conditions. Questionnaires are returned by pre-stamped mail.

    Time frame: Baseline (Day 1) and 6 months post-discharge (Day 180 ± 7 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — This is a pilot, monocentric study with a limited sample size of 34 participants. The decision to share individual participant data has not yet been made. It will depend on the nature and scope of future publications, the feasibility of adequate deidentification given the small cohort size, and compliance with applicable French data protection regulations (General Data Protection Regulation and MR-001 reference methodology). A data sharing plan will be defined at the time of publication, in accordance with journal requirements and applicable ethical and legal frameworks.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 1,231 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 14 months is above that.

Counting every sponsor, half of 1,286 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731204
Lead sponsor
LNA SANTE
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Eva MRS BRIAND
Contact
eva.briand@lna-sante.com
(0)240160161 ext +33
Mathieu Mr LEDUCQ
principal investigator · LNA SANTE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion